A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase NA Terminated
1 enrolled
ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
EXPAND
Phase 2 Terminated
2 enrolled 8 charts
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1/2 Terminated
8 enrolled 11 charts
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1/2 Terminated
200 enrolled
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Phase 2 Terminated
3 enrolled 7 charts
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
DC15-MM-01
Phase 1 Terminated
4 enrolled
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Phase 1 Terminated
12 enrolled
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
Phase 1 Terminated
3 enrolled
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
66 enrolled
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1/2 Terminated
6 enrolled 17 charts
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled
LuminICE-203
Phase 2 Terminated
25 enrolled 21 charts
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
A Study to Investigate LYL845 in Adults With Solid Tumors
Phase 1 Terminated
39 enrolled
START
Terminated
10 enrolled
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
45 enrolled
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Phase 1/2 Terminated
40 enrolled
MK-0482-002
Phase 1 Terminated
13 enrolled 19 charts
FIRCE-1
Phase 2 Terminated
101 enrolled
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Phase 1 Terminated
62 enrolled
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Phase 2 Terminated
7 enrolled 11 charts
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
183 enrolled
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1/2 Terminated
57 enrolled 31 charts
MCLA-117 in Acute Myelogenous Leukemia
Phase 1 Terminated
80 enrolled
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Phase 1 Terminated
45 enrolled
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Phase 1 Terminated
13 enrolled
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
PETEY
Phase 2 Terminated
25 enrolled 23 charts
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Terminated
9 enrolled 11 charts
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Phase 1 Terminated
64 enrolled
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
60 enrolled
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
9 enrolled
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
3 enrolled
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase 1 Terminated
139 enrolled
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
19 enrolled 22 charts
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Phase 2/3 Terminated
5 enrolled 15 charts
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Phase 1 Terminated
11 enrolled
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
47 enrolled
ARMY
Phase 1 Terminated
71 enrolled 26 charts
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Phase 1/2 Terminated
79 enrolled
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Phase 1 Terminated
1 enrolled
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Phase 1/2 Terminated
79 enrolled 18 charts